ArticleExperimental hematology & oncology2022

The HSP90 inhibitor KW-2478 depletes the malignancy of BCR/ABL and overcomes the imatinib-resistance caused by BCR/ABL amplification.

Dachuan Zeng et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.